AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$SIBN

PISETSKY MICHAEL A. sold $656K of SIBN

PISETSKY MICHAEL A. (SVP, Ops & Adm/Chief Legal Ofr) sold 29,665 shares of SI-BONE, Inc. (SIBN) at $22.10 ($0.66M total) on 2026-10-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · PISETSKY MICHAEL A.
Published Nov 2, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SIBN
Bearish
medium confidence
Mentioned
$SIBN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, but the amount is modest relative to total shares outstanding.

02

Market read

A small insider sell; likely limited price effect unless compounded by other news.

03

What to watch

Potential upcoming product approvals or earnings could offset the sell signal.

Relevance 4/10Novelty 4/10Timing: filing date 2026-11-02, after‑hours

Background

SI‑BONE is a medical device company specializing in spinal implants. Insider transactions are publicly reported via Form 4 filings.

Company-level read

Ticker impact

$SIBNBearishMedium confidence
Context

Form 4 disclosed that SVP Michael Pisesky sold 29,665 shares of SI-BONE at $22.105 per share, totaling $655,744.82.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

C‑level insider selling, even at modest size, often leads to short‑term downside bias, especially when no offsetting news is present.

Market effects

Sector

Minimal impact on orthopedic device sector; isolated insider transaction.

Regional

No broader regional effect.

Global

Limited to SI‑BONE investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook; price may remain stable.

Key entities

  • Officer
    Michael A. Pisesky

    SVP, Operations & Administration / Chief Legal Officer at SI‑BONE

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SIBN insider trading history →

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com
$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

finance.yahoo.com
$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.

finance.yahoo.com